Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enteric-coated Hydroxypropyl Methylcellulose Empty Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enteric-coated Hydroxypropyl Methylcellulose Empty Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical and nutraceutical formulators, encapsulating acid-sensitive active ingredients (probiotics, enzymes, peptides) or drugs that cause gastric irritation requires protection from stomach acid (pH 1.5-3.5) with targeted release in the small intestine (pH 5.5-7.0). Traditional gelatin capsules dissolve in the stomach, offering no protection; enteric-coated gelatin capsules involve a secondary coating step. The enteric-coated HPMC empty capsule addresses this through plant-based delayed release: capsules made from hydroxypropyl methylcellulose (HPMC, plant-derived, vegetarian) with an integrated enteric coating that remains intact in gastric conditions and dissolves selectively in the small intestine. According to QYResearch’s updated model, the global market for Enteric-coated Hydroxypropyl Methylcellulose Empty Capsules was estimated to be worth US$ 341 million in 2025 and is projected to reach US$ 513 million, growing at a CAGR of 6.1% from 2026 to 2032. Enteric-coated Hydroxypropyl Methylcellulose (HPMC) empty capsules are plant-derived capsules made from hydroxypropyl methylcellulose, coated with an enteric layer that remains stable in acidic gastric conditions and dissolves selectively in the higher pH environment of the small intestine. They exhibit excellent biocompatibility and safety, making them suitable for encapsulating acid-sensitive or gastric-labile active pharmaceutical ingredients, probiotics, enzymes, and other functional compounds. Compared with traditional gelatin capsules, HPMC capsules are free of animal-derived ingredients, suitable for vegetarians and individuals with allergies to animal proteins. They are widely used in both pharmaceutical and nutraceutical formulations, particularly for oral dosage forms requiring precise control over release site and timing. In 2024, the global sales volume of enteric-coated hydroxypropyl methylcellulose (HPMC) empty capsules reached 103.5 billion capsules, with an average price of 31 USD per 10,000 capsules.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098128/enteric-coated-hydroxypropyl-methylcellulose-empty-capsules
1. Technical Architecture: Capsule Sizes and Enteric Coating Technology
Enteric-coated HPMC empty capsules are segmented by size (capacity), determining fill volume and application:
| Capsule Size | Fill Volume (mL) | Typical Applications | Price per 10,000 capsules (USD) | Market Share (Units) |
|---|---|---|---|---|
| 00# | 0.91-0.95 | High-dose pharmaceuticals, probiotics (50B+ CFU) | $35-45 | 15% |
| 0# | 0.68-0.72 | Standard pharmaceuticals, nutraceuticals | $32-40 | 25% |
| 1# | 0.48-0.52 | Probiotics, enzymes, herbal extracts | $30-38 | 30% |
| 2# | 0.36-0.40 | Small-dose pharmaceuticals, pediatric formulations | $28-35 | 15% |
| 3# | 0.27-0.30 | Low-dose APIs, specialty applications | $26-32 | 10% |
| Others (4#, 5#, 0el) | 0.20-1.00 | Custom, veterinary, clinical trials | $25-50 | 5% |
Key technical challenge – consistent enteric coating without capsule deformation: Over the past six months, several advancements have emerged:
- Lonza (February 2026) introduced a “one-step” enteric-coated HPMC capsule (Capsugel Enprotect) with integrated enteric polymer (no secondary coating), reducing manufacturing cost by 20% and eliminating coating variability.
- ACG Associated Capsules (March 2026) commercialized a “pH-7″ enteric coating dissolving at pH 7.0 (ileal release), targeting colonic drug delivery (IBD, colonic cancer).
- Qualicaps (January 2026) launched an enteric-coated HPMC capsule with “acid protection” tested for 2 hours in 0.1N HCl (simulated gastric fluid) with <10% drug release, >90% release in phosphate buffer pH 6.8 within 45 minutes.
Industry insight – enteric-coated capsule vs. tablet comparison:
| Parameter | Enteric-coated HPMC Capsule | Enteric-coated Tablet |
|---|---|---|
| Manufacturing complexity | Lower (fill into pre-coated capsule) | Higher (coating tablet cores) |
| Acid protection | Excellent (capsule intact) | Excellent (coated) |
| Release site | Small intestine (pH-dependent) | Small intestine (pH-dependent) |
| Suitability for liquids/pastes | Yes (liquid fills, semi-solids) | No (requires solid formulation) |
| Vegetarian | Yes (HPMC) | Yes (depends on binder) |
| Cost per dose | $0.003-0.005 | $0.002-0.004 |
2. Market Segmentation: Capsule Size and Application
The Enteric-coated Hydroxypropyl Methylcellulose Empty Capsules market is segmented as below:
Key Players: Qualicaps (US/Spain), Lonza (Switzerland/US), ACG Associated Capsules (India), Suheung (South Korea), CapsCanada (Canada), Sunil Healthcare (India), Evonik Specialty Chemicals (Germany), Shandong Healsee Capsule (China), Anhui Huangshan Capsule (China), Farmacapsulas (Colombia), Guangzhou Jiuzhou Capsule (China), Hunan Er-Kang Pharmaceutical (China), Hebei Kangxin Plant Capsule (China), Zhejiang Yueshan Capsule (China), Zhejiang Tianlong Capsule (China), Zhejiang Xinchang Kangping Capsule (China), Jiangsu Kangyoujian Biotechnology (China), Guizhou Guang De Li Pharmaceuticals (China), SUZHOU CAPSUGEL (China), Chongqing Heng Sheng Pharmaceutical (China), Jiangsu Youli Capsule (China), Jinan Gaohua Medicinal Capsule (China)
Segment by Capsule Size:
- 1# – Largest segment (30% of 2025 units). Most common for nutraceuticals (probiotics, enzymes).
- 0# – 25% of units. Standard pharmaceutical capsules.
- 00# – 15% of units. High-dose products.
- 2# – 15% of units. Small-dose products.
- 3# – 10% of units. Low-dose specialty.
- Others – 5% of units.
Segment by Application:
- Pharmaceuticals – Largest segment (55% of revenue). Acid-sensitive drugs (proton pump inhibitors, mesalamine, budesonide), gastric-irritant drugs (NSAIDs, iron supplements).
- Health Supplements (Nutraceuticals) – 40% of revenue (fastest-growing, 8% CAGR). Probiotics (Lactobacillus, Bifidobacterium, Saccharomyces boulardii), digestive enzymes (lipase, protease, amylase), fish oil (burp-less), herbal extracts.
- Others – Veterinary, clinical trial supplies (5% of revenue).
Typical user case – probiotic encapsulation for gut delivery: A probiotic manufacturer produces 10 billion CFU capsules (Lactobacillus acidophilus + Bifidobacterium longum). Standard gelatin capsules release probiotics in stomach (pH 1.5-3.5), where 90-99% of bacteria are killed by gastric acid. Enteric-coated HPMC capsules (size 1#, ACG) protect probiotics through stomach, release in small intestine (pH 6.8), achieving 50-100x higher survival (1-10% vs. 0.1-1%). Cost premium: $0.002 per capsule ($0.02 per bottle of 10 capsules). Value: superior clinical efficacy, premium pricing (+30-50%).
Exclusive observation – “burp-less” fish oil capsules: Fish oil supplements often cause fishy burps (eructation) due to gastric release and oxidation. Enteric-coated HPMC capsules delay release to small intestine, eliminating burping. “Burp-less” fish oil segment growing at 10% CAGR, commanding 50% price premium. Market leaders: Nordic Naturals, Carlson Labs, NOW Foods.
3. Regional Dynamics and Probiotics Growth
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| Asia-Pacific | 45% | Largest capsule manufacturing base (China, India, South Korea), domestic manufacturers (Healsee, Huangshan, Jiuzhou, Er-Kang, Kangxin, Yueshan, Tianlong, Kangping, Kangyoujian, Guang De Li, Suzhou Capsugel, Heng Sheng, Youli, Gaohua), cost leadership |
| North America | 25% | Large nutraceutical market (probiotics, enzymes), vegetarian demand |
| Europe | 20% | Strong pharmaceutical industry (Germany, Switzerland, France), Lonza/Qualicaps/Evonik leadership |
| RoW | 10% | Emerging nutraceuticals (Latin America – Farmacapsulas, Middle East) |
Exclusive observation – “vegetarian capsule” growth driver: HPMC capsules (plant-derived) are vegetarian (vs. gelatin from animal collagen). Vegetarian/Vegan consumer segment growing at 10% annually (estimated 10-15% of Western population, higher in Asia). Enteric-coated HPMC capsules command 20-30% price premium over gelatin. “Plant-based” labeling is a key marketing advantage.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global leaders | Lonza (Switzerland), Qualicaps (US/Spain), ACG (India), Suheung (Korea), CapsCanada (Canada), Evonik (Germany) | Full size range, integrated enteric coating, global distribution, premium pricing (+20-30%) |
| 2 | Chinese domestic leaders | Shandong Healsee, Anhui Huangshan, Guangzhou Jiuzhou, Hunan Er-Kang, Hebei Kangxin, Zhejiang Yueshan, Zhejiang Tianlong, Zhejiang Kangping, Jiangsu Kangyoujian, Guizhou Guang De Li, Suzhou Capsugel, Chongqing Heng Sheng, Jiangsu Youli, Jinan Gaohua | Cost leadership (30-50% below global), domestic market dominance, export |
| 2 | Regional specialists | Farmacapsulas (Colombia), Sunil Healthcare (India) | Regional markets, cost-competitive |
Technology roadmap (2027-2030):
- Colonic delivery HPMC capsules – Enteric coating dissolving at pH 7.0-7.5 (ileum) for targeted delivery to colon (IBD, colorectal cancer). Pilot stage.
- Time-controlled release capsules – Combination of enteric coating + internal barrier layers for pulsatile or sustained release.
- HPMC capsules for liquid fills – Enteric-coated capsules compatible with non-aqueous liquid fills (oils, PEG solutions), expanding application to softgel alternatives.
With 6.1% CAGR and 103.5 billion capsules sold in 2024, the enteric-coated HPMC empty capsule market benefits from probiotic growth, vegetarian/vegan demand, and acid-sensitive drug delivery. Key growth drivers: gut health awareness (probiotics), plant-based movement, and pharmaceutical reformulation (gastric protection). Risks include competition from enteric-coated tablets (lower cost for high-volume), regulatory barriers (novel excipient approval), and manufacturing complexity (coating consistency).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
